Re Oxford NanoLabs

IP Group PLC
28 March 2008



28 MARCH 2008



          SPIN-OUT COMPANY OXFORD NANOLABS COMPLETES £10M FUNDRAISING



IP Group plc (LSE: IPO) ('IP Group' or the 'Company' or 'Group'), the UK's
leading university intellectual property commercialisation company, is delighted
to note that Oxford NanoLabs Limited ('Oxford NanoLabs' or 'ONL'), a spin-out
company from the University of Oxford, has successfully completed a £10 million
financing round.



Oxford NanoLabs, founded in 2005, is developing nanopore technology for use in
DNA sequencing, where it potentially offers significant advantages in cost and
speed over existing technologies.



Following completion of the financing round, IP Group has a 35% beneficial stake
in Oxford NanoLabs, valued at £19.5 million. IP Group has invested £1 million in
the financing alongside investment of £1.4 million from funds managed by Top
Technology Ventures Limited, a subsidiary of IP Group. The remaining £7.6
million was raised from institutional and private investors.



The fundraising will result in a total fair value gain to IP Group of £7.2
million.



For further information, please contact:



IP Group plc

0845 0742929

Alan Aubrey, Chief Executive Officer

Liz Vaughan-Adams (Communications)

020 7444 0062/07979853802



Financial Dynamics

Ben Atwell, Rob Bailhache, Sanjeev Pandya

020 7831 3113



Oxford NanoLabs

Dr Gordon Sanghera, Chief Executive Officer

0870 486 1966

Zoe McDougall (Communications)



Notes for Editors



About IP Group



IP Group is an intellectual property (IP) commercialisation company that
specialises in commercialising university technology. Founded in 2001, IP Group
listed on AIM in October 2003 and moved to the Official List in June 2006. It
has made two acquisitions to date - Techtran, a company set up to commercialise
university intellectual property under a long term contract with the University
of Leeds, in 2005 and Top Technology Ventures, an investment adviser to early
stage technology venture capital funds, in 2004.



IP Group has formed long-term partnerships with ten universities - the
University of Oxford, King's College London, CNAP/University of York, the
University of Leeds, the University of Bristol, the University of Surrey, the
University of Southampton, Queen Mary (University of London), the University of
Bath and the University of Glasgow.



The Company's portfolio is diverse with exposure to five main sectors - Energy &
Renewables, Healthcare & Life Sciences: Non-therapeutics, Healthcare & Life
Sciences: Therapeutics, IT & Communications and Chemicals & Materials. To date,
ten portfolio companies have listed on the AIM market of the London Stock
Exchange, one on PLUS Markets and there have been two trade sales. IP Group also
established three 'Modern-themed' subsidiaries - Modern Biosciences, Modern
Water and Modern Waste. Modern Water was the first of these subsidiaries to
float on AIM in June 2007.



For more information, please visit our website at www.ipgroupplc.com.



About Oxford NanoLabs



Oxford NanoLabs is dedicated to the development of nanopore technology, to power
a revolution in DNA analysis. In contrast to current technologies,
nanopore-based DNA analysis has the potential to measure single molecules
without the need for chemical labels, therefore avoiding the use of expensive
reagents and time-consuming amplification steps.  Direct electrical measurement
of the DNA sequence allows simpler instrumentation and data processing.

The Company's proprietary BASETM technology is being developed to use nanopores
to process, identify and record DNA bases in sequence. As each base is passed
sequentially through the nanopore, it binds transiently to a site within the
nanopore. During binding each base generates a characteristic reduction of the
electrical current through the nanopore, allowing for direct recording of the
signal and simple data processing.

Oxford NanoLabs aims to use this elegant and scalable method of analysis to
transform the speed and cost of DNA sequencing.  There is demand for a new
generation of powerful and affordable genome sequencing technology that would
facilitate a dramatic expansion in genomic research. This is characterised by
the explosive interest in the race for the '$1000 genome', a common phrase that
describes a tipping-point where DNA sequencing becomes so affordable and
accessible that research and understanding of the genome would increase
exponentially. A new, disruptive sequencing technology has the potential to
enable a new era of genomic applications in medicine, the environment,
agriculture and many other areas.

Oxford NanoLabs received seed funding from IP Group plc in 2005 and a further
£7.75 million was raised in a private round in 2006.

For further information please visit www.oxfordnanolabs.com.






                      This information is provided by RNS
            The company news service from the London Stock Exchange